Chronic Myelomonocytic Leukemia Drug Pipeline: 31 Assets by Phase

How many chronic myelomonocytic leukemia drugs are in each phase of development?

Douglas Insights counts 2 chronic myelomonocytic leukemia candidates in Phase III, 6.5% of the 31 assets in development; Phase II holds 10 and Phase I holds 19.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each chronic myelomonocytic leukemia asset appears in exactly one row. The 97 trials still recruiting or running carry 46% of the 211 registered trials in scope.

How many chronic myelomonocytic leukemia trials are recruiting patients now?

52 chronic myelomonocytic leukemia trials are recruiting patients and 5 more have not started recruiting yet, out of 211 interventional trials in scope; together they make up 27% of the trial base.

Terminated, suspended and withdrawn chronic myelomonocytic leukemia trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the chronic myelomonocytic leukemia pipeline?

Novartis Pharmaceuticals leads the chronic myelomonocytic leukemia pipeline with 4 candidates; the top 5 sponsors hold 42% of the 31 assets, and 23 sponsors run at least one.

Industry sponsors lead 67 of the 211 chronic myelomonocytic leukemia trials (32%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the chronic myelomonocytic leukemia pipeline?

Mechanism and drug-type classification for the 31 chronic myelomonocytic leukemia candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What chronic myelomonocytic leukemia trial readouts are coming next?

4 chronic myelomonocytic leukemia candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many chronic myelomonocytic leukemia readouts fall in each quarter?

9 chronic myelomonocytic leukemia candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 3, due in Q1 2028.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most chronic myelomonocytic leukemia trials?

United States hosts the most chronic myelomonocytic leukemia trials, with sites in 168 of the 211 studies (80%); trials in scope run in 50 countries in all.

A multinational chronic myelomonocytic leukemia trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are chronic myelomonocytic leukemia drugs being tested?

168 of the 211 chronic myelomonocytic leukemia trials (80%) have a site in the United States, 44 (21%) in Europe and 13 (6.2%) in China; 27 of the 31 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational chronic myelomonocytic leukemia trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the chronic myelomonocytic leukemia pipeline since the last update?

Since 3 Oct 2026, the chronic myelomonocytic leukemia pipeline count moved by +1 assets to 31, Phase III moved by 0 and the trial base by 0.

How does Douglas Insights count the chronic myelomonocytic leukemia pipeline?

Douglas Insights read 211 interventional trials registered on ClinicalTrials.gov for the conditions "Leukemia, Myelomonocytic, Chronic", "CMML" and updated since 3 Oct 2021, then grouped every drug or biologic named in them into 31 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the chronic myelomonocytic leukemia pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage